Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

T7205

Sigma-Aldrich

Tegafur

≥98% (HPLC), powder

Sinonimo/i:

5-Fluoro-1-(tetrahydro-2-furyl)uracil, Ftorafur, Tegafur

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C8H9FN2O3
Numero CAS:
17902-23-7
Peso molecolare:
200.17
Numero CE:
241-846-2
Numero MDL:
MFCD00012351
Codice UNSPSC:
12352200
ID PubChem:
329826861
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to off-white

Punto di fusione

171-173 °C (lit.)

Solubilità

DMSO: >50 mg/mL

Temperatura di conservazione

room temp

Stringa SMILE

FC1=CN(C2CCCO2)C(=O)NC1=O

InChI

1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
WFWLQNSHRPWKFK-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Tegafur has been used as an internal standard for the analysis of 5′DFCR (5′deoxyfluorocytidine) and 5′DFUR (5′deoxyfluorouridine) using HPLC techniques. Tegafur has also been used as an internal standard for the chromatographic assay of azidothymidine (AZT).

Azioni biochim/fisiol

Tegafur is a pro-drug of 5-fluorouracil, an antimetabolite used as an antineoplastic agent. It has been used as adjuvant chemotherapy for curatively resected colorectal cancer therapy.

Nota sulla preparazione

Tegafur is soluble in DMSO at a concentration that is greater than 50 mg/ml.

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H301 + H311 + H331

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
043M4714V
021M4722V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Thierry Besnard et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 870(1), 117-120 (2008-06-20)
The 5FU prodrug capecitabine undergoes a 3-step enzymatic conversion, including the conversion of 5'DFRC into 5'DFUR by cytidine deaminase (CDA). The presence of CDA activity in blood led us to analyze the possible ex vivo conversion of 5'DFCR into 5'DFUR
Terence C Tang et al.
Neoplasia (New York, N.Y.), 12(3), 264-274 (2010-03-18)
Hepatocellular carcinoma (HCC) is an intrinsically chemotherapy refractory malignancy. Development of effective therapeutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcutaneous human tumor transplants in immunodeficient mice; however, these do not reproduce the
Muhammad Wasif Saif et al.
Expert opinion on investigational drugs, 18(3), 335-348 (2009-02-27)
S-1 is an oral fluoropyrimidine that is designed to improve the antitumor activity of 5-fluorouracil (5-FU) concomitantly with an intent to reduce its toxicity. S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or
Li-Feng Liu et al.
Chinese medical journal, 125(11), 1931-1935 (2012-08-14)
The pharmacokinetics of zidovudine (AZT) are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed
T Yoshimasu et al.
European journal of dermatology : EJD, 11(1), 54-57 (2001-02-15)
A mixture of uracil and tegafur (UFT) is a common antineoplastic agent in Japan. We report a 64-year-old Japanese woman with discoid lupus erythematosus (DLE)-like lesions which were induced by UFT. After surgery to treat lung cancer, UFT (300 mg/day)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.